Strain-specific influenza vaccine immunogenicity in adults with severe asthma receiving biologic therapy: a real-world baseline-adjusted HAI study

Background Evidence on influenza vaccine immunogenicity during biologic treatment for severe asthma remains limited, particularly in adults treated in routine clinical practice. Methods In this prospective single-centre observational study, we analysed pre- and post-vaccination haemagglutination-inhibition (HAI) titres in 147 adults with asthma who received Grippol Quadrivalent during the 2023–2024 season: 126 patients with severe asthma receiving ongoing biologic therapy and 21 asthma controls not receiving biologic therapy. Blood was obtained before vaccination and 4–6 weeks after vaccination. For each vaccine strain, log2(post-vaccination HAI) was modelled using analysis of covariance with study group and the corresponding log2(pre-vaccination HAI) titre as predictors. The group coefficient was back-transformed to an adjusted geometric mean ratio (GMR; biologic therapy/control). Results Adjusted GMRs were 0.61 (95% CI 0.33–1.13; P = 0.113) for A/H1N1/Victoria, 1.08 (0.64–1.81; P = 0.779) for A/H3N2/Darwin, 0.46 (0.23–0.94; P = 0.032) for B/Austria, and 0.59 (0.34–1.05; P = 0.073) for B/Phuket. Conclusion Baseline-adjusted estimates differed numerically across strains, but between-strain heterogeneity was not formally tested.B/Austria yielded a nominally lower adjusted titre (P = 0.032; Holm-adjusted P = 0.128), but not after additional adjustment for age and sex (GMR 0.54, 95% CI 0.28–1.05; P = 0.068); confidence intervals for the other three strains included unity; all findings are exploratory. These observational data extend randomized evidence from individual biologics to an adult real-world severe-asthma cohort.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-12
DOI
https://doi.org/10.3389/fimmu.2026.2015200
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Strain-specific influenza vaccine immunogenicity in adults with severe asthma receiving biologic therapy: a real-world baseline-adjusted HAI study

М. П. Костинов, В. Б. Полищук, Irina Leonidovna Soloveva, Aristitsa Mikhailovna Kostinova et al.
Frontiers in Immunology
Influenza Virus Research Studies
article

Strain-specific influenza vaccine immunogenicity in adults with severe asthma receiving biologic therapy: a real-world baseline-adjusted HAI study

М. П. Костинов, В. Б. Полищук, Irina Leonidovna Soloveva, Aristitsa Mikhailovna Kostinova, Хамидулина Анна Анатольевна, Natalia Andreeva, Albahansa Yvette Mana, Lilia Gladkova, Al’bina Khasanova, Anton Kostinov, Anna Shmitko
article en

Abstract

Background Evidence on influenza vaccine immunogenicity during biologic treatment for severe asthma remains limited, particularly in adults treated in routine clinical practice. Methods In this prospective single-centre observational study, we analysed pre- and post-vaccination haemagglutination-inhibition (HAI) titres in 147 adults with asthma who received Grippol Quadrivalent during the 2023–2024 season: 126 patients with severe asthma receiving ongoing biologic therapy and 21 asthma controls not receiving biologic therapy. Blood was obtained before vaccination and 4–6 weeks after vaccination. For each vaccine strain, log2(post-vaccination HAI) was modelled using analysis of covariance with study group and the corresponding log2(pre-vaccination HAI) titre as predictors. The group coefficient was back-transformed to an adjusted geometric mean ratio (GMR; biologic therapy/control). Results Adjusted GMRs were 0.61 (95% CI 0.33–1.13; P = 0.113) for A/H1N1/Victoria, 1.08 (0.64–1.81; P = 0.779) for A/H3N2/Darwin, 0.46 (0.23–0.94; P = 0.032) for B/Austria, and 0.59 (0.34–1.05; P = 0.073) for B/Phuket. Conclusion Baseline-adjusted estimates differed numerically across strains, but between-strain heterogeneity was not formally tested.B/Austria yielded a nominally lower adjusted titre (P = 0.032; Holm-adjusted P = 0.128), but not after additional adjustment for age and sex (GMR 0.54, 95% CI 0.28–1.05; P = 0.068); confidence intervals for the other three strains included unity; all findings are exploratory. These observational data extend randomized evidence from individual biologics to an adult real-world severe-asthma cohort.

Frontiers in ImmunologyVol. 17
Sechenov University (RU), Ulyanovsk State University (RU), Mari State University (RU), Research Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences (RU)
Good health and well-being
Influenza Virus Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon